Study of the safety of unlicensed cord blood units for stem cell transplant of children and adults.

For the treatment arm of this study you will no receive the total body radiation (TBI) as typically given before transplant. In this study you will have various research procedures such as a Blast sample at the screening part of the study, and MRD testing of your bone marrow and blood at screening and through the course of the study. Participation in the treatment arm (Non-TBI) of the study will last up to 5 years.

This is a multi-center project in which the American Thrombosis & Hemostasis Network (ATHN) will offer free genotyping to individuals with Rare Coagulation Disorders (RCD).

One tube of blood will be collected during a routine clinic visit.

This is a survey and interview study recruiting patients with sickle cell disease (SCD). Participants will answer questionnaires and complete a remote interview about health care experiences, pain, and discrimination. Natural language processing of interview transcripts will be used to quantify linguistic features indicative of subjective associations between individual experiences of racial discrimination and sickle cell pain.

Participants will be asked to fill out questionnaires and answer questions during an interview.

$50

The purpose of this prospective, multi-site study is to conduct a clinical evaluation of the investigational CN-6000 device using venous plasma specimens from adult participants in different care settings with various disease processes. This is a fully automated blood coagulation analyzer intended for in-vitro diagnostic use to analyze clotting, chromogenic and immuno-chemical methods in 3.2% Na citrated plasma in a clinical laboratory. No more than 2 venous blood draws will be attempted to obtain up to 4 whole blood specimens per subject, totaling no more than 30 mL. Samples may also be tested on the CS-5100 predicate comparator device.

This study will require 1 visit to Hershey Medical Center on a single day for up to two blood draws, no more than 2 tablespoons of blood (30 ml) total. The visit should last no more than 60 minutes and will be scheduled in advance with the study team. This visit will include signing a consent form to participate in the study, allowing the study team to draw your blood, and providing a small amount of information about yourself. We are looking for volunteers with coagulation disorders and healthy volunteers.

$75

Specific guidance is lacking for pregnant women with von Willebrand Disease (VWD) and delivery planning in terms of how high a von Willebrand factor (VWF) level should be achieved. Specifically, guidance is lacking on whether replacement therapy drugs (Wilate & Tranexamic Acid) should target a VWF minimum level. This study is a prospective study to document the rate of primary postpartum hemorrhage (PPH) and the effectiveness of the dosing of Wilate, looking to provide increased management and guideline recommendations.

Pregnant women will come to clinic at 34-38 weeks of pregnancy, observation at time of labor or C-Section, during delivery,72 hrs. post delivery & 5-7 days vaginal delivery or 7-10 days if C-Section.